Literature DB >> 9711843

An extended-spectrum AmpC-type beta-lactamase obtained by in vitro antibiotic selection.

M I Morosini1, M C Negri, B Shoichet, M R Baquero, F Baquero, J Blázquez.   

Abstract

A predictive approach was assayed to evaluate the possibility of mutant Amp-C beta-lactamase emergence with increased substrate spectrum (including new C-3' quaternary ammonium cephems). The ampC gene encoding the AmpC beta-lactamase from Enterobacter cloacae was cloned and expressed in an AmpC-defective strain of E. coli. After the AmpC containing strain was challenged with cefpirome, an ampC variant encoding an enzyme with increased resistance to cefpirome and cefepime was selected. In addition, this variant conferred increased resistance to penicillins and third generation cephalosporins. The complete nucleotide sequence of the gene was determined. The deduced peptide sequence showed a single change with respect to the wild-type gene: valine to glutamic acid at position 318 of the native protein (298 of the mature enzyme). The potential emergence and spread of this type of AmpC variants among pathogens should be considered.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9711843     DOI: 10.1111/j.1574-6968.1998.tb13131.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN: 0378-1097            Impact factor:   2.742


  16 in total

Review 1.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 2.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.

Authors:  R A Powers; J Blázquez; G S Weston; M I Morosini; F Baquero; B K Shoichet
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

4.  Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center.

Authors:  P E Coudron; E S Moland; K S Thomson
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

5.  Mutation in Serratia marcescens AmpC beta-lactamase producing high-level resistance to ceftazidime and cefpirome.

Authors:  A Raimondi; F Sisto; H Nikaido
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

6.  Biochemical-genetic characterization and regulation of expression of an ACC-1-like chromosome-borne cephalosporinase from Hafnia alvei.

Authors:  D Girlich; T Naas; S Bellais; L Poirel; A Karim; P Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Mutational replacement of Leu-293 in the class C Enterobacter cloacae P99 beta-lactamase confers increased MIC of cefepime.

Authors:  Sergei B Vakulenko; Dasantila Golemi; Bruce Geryk; Maxim Suvorov; James R Knox; Shahriar Mobashery; Stephen A Lerner
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

8.  Dissemination of SHV-12 and characterization of new AmpC-type beta-lactamase genes among clinical isolates of enterobacter species in Korea.

Authors:  Sang Hee Lee; Jae Young Kim; Sang Heum Shin; Young Jun An; Young Wook Choi; Yeun Chang Jung; Ha Il Jung; Eui Suk Sohn; Seok Hoon Jeong; Kye Joon Lee
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

9.  AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.

Authors:  Hedi Mammeri; Hasan Nazic; Thierry Naas; Laurent Poirel; Sophie Léotard; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Structural bases for stability-function tradeoffs in antibiotic resistance.

Authors:  Veena L Thomas; Andrea C McReynolds; Brian K Shoichet
Journal:  J Mol Biol       Date:  2009-11-10       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.